Regulation of nicotine-evoked dopamine release from PC12 cells.
The nature of second messengers involved in the nicotine-evoked release of dopamine from PC12 cells was examined. Calmidazolium, a calmodulin inhibitor, abolished the nicotine-evoked release. A23187, a Ca2+ ionophore, enhanced dopamine release, and this was inhibited by calmidazolium. Further, 2', 5'-dideoxyadenosine abolished both the nicotine- and A23187-evoked release. Forskolin, dibutyryl-cyclic AMP, and rolipram (a cyclic AMP phosphodiesterase inhibitor) all enhanced dopamine release. 1, 9-Dideoxyforskolin, a forskolin analog which does not activate adenylate cyclase, did not alter dopamine release. These results suggest an obligatory role for Ca2+ and calmodulin-sensitive adenylate cyclase in the nicotine-evoked release process.
Courtney
N D
ND
VA Medical Center Research Service, Portland, OR 97201.
Howlett
A C
AC
Westfall
T C
TC
D000262:Adenylyl Cyclases / Q000378:metabolism; D000310:Adrenal Gland Neoplasms / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D016048:Dideoxyadenosine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D007424:Intracellular Fluid / Q000378:metabolism; D009538:Nicotine / Q000494:pharmacology*; D010673:Pheochromocytoma / Q000378:metabolism / Q000473:pathology; D051381:Rats; D011978:Receptors, Nicotinic / Q000187:drug effects; D014407:Tumor Cells, Cultured
D011978:Receptors, Nicotinic; D005576:Colforsin; D000001:Calcimycin; D016048:Dideoxyadenosine; D009538:Nicotine; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D002118:Calcium; D004298:Dopamine